News headlines Vertex Pharmaceuticals (VRTX) is gaining attention with promising developments in kidney treatments and solid earnings growth, although concerns linger about its reliance on cystic ...
EHA: Vertex, CRISPR build case for gene-editing drug A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has continued to show impressive results in clinical trial, with an update ...
Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without regular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback